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Correct recognition of butyrylcholinesterase (BChE; EC 3.1.1.8) variants in human serum is essential if 
patients susceptible to a prolonged reaction following treatment with short acting muscle relaxants, like 
suxamethonium, are to be reliably identified. The dimethylcarbamate Ro 02-0683 is used in standard 
procedures for identification of BChE variant by measuring residual activity after two hours of inhibition. 
Such a long inhibition time distinguishes well between the usual (U) and atypical (A), but less successfully 
the fluoride-resistant (F) variant. In this paper, inhibition rate constants were determined from the initial 
time course of inhibition of homozygous (FF) and heterozygous (UF and AF) BChE phenotypes by Ro 
02-0683; 1.6x106, 2.7x106 and 6.2x106 dm3 mol-1 min-1 for AF, FF and UF, respectively. After only 30 
min of inhibition the resolution between the phenotypes was even better than after two hours. Hence, 
determination of the residual activity after 30 min inhibition is recommended for the segregation of the 
suxamethonium sensitive fluoride-resistant variants.
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The serum butyrylcholinesterase (BChE; EC 
3.1.1.8) activity in humans is of major clinical 
importance in several therapeutic fields as well as in 
the toxicology of natural and synthetic poisons (1, 2). 
The importance of BChE in the hydrolysis of several 
drugs, especially the muscle relaxant suxamethonium 
(succinyldicholine) is well established (3-5). At least 
20 different, naturally occurring BChE variants have 
been characterized by nucleotide substitution, deletion 
or insertion which result in alterations to the BChE 
protein giving different catalytic properties, and partial 
or complete absence of protein (6). The approximate 
frequency of homozygous BChE genotypes in 
Caucasian populations is 95 % for the usual (UU), 1 
in 160000 for fluoride-resistant (FF) and 1 in 2500 
for atypical (AA) enzyme. That for heterozygous 
BChE is 1 in 30 for usual-fluoride-resistant (UF) 
and 1 in 19000 for the atypical-fluoride-resistant 
(AF) (3). After receiving suxamethonium individuals 
with the fluoride-resistant (F) and atypical (A) BChE 
alleles may experience an apnea, in excess of the 3-
5 min expected in individuals with usual BChE (4). 
Therefore, individuals with AF and FF phenotypes are 
at moderate risk (4). 
Two fluoride-resistant variants have been recognised 
and characterized by nucleotide substitution changing 
Thr 243 to Met (Fluoride-1 variant) or Gly 390 to Val 
(Fluoride-2 variant) (7). Fluoride-2 occurs more 
frequently than the fluoride-1 variant (7).
The fluoride-resistant variant of human BChE 
owes its name to the observation that it is resistant 
to inhibition by 50 µM sodium fluoride in in vitro 
assays (8). Standard phenotyping methods require 
measurement of BChE activity and the degree of 
inhibition by sodium fluoride, dibucaine and the 
dimethylcarbamate, Ro 02-0683 (3). Due to the lack 
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of sharp boundaries between phenotyping data (the 
range of activities and inhibitor numbers overlaps) it 
is sometimes difficult to assign a definite phenotype, 
especially for heterozygous alleles. Dibucaine and 
sodium fluoride are reversible inhibitors of BChE, 
and the degree of inhibition depends on the type 
and concentration of substrate used in the assay. 
Moreover, sodium fluoride, although efficient for the 
detection of fluoride-resistant variants, is a difficult 
inhibitor to handle specially because its inhibition is 
strongly temperature dependent. 
Dimethylcarbamate Ro 02-0683 (Figure 1) 
irreversibly inhibits BChE carbamoylating the enzyme 
catalytic centre, serine 198. Inhibition by Ro 02-0683 
provides good supportive information on BChE 
phenotypes, but some workers find it inconvenient 
because of the required 2 h preincubation of enzyme 
with inhibitor (3). After 2 hours the reaction between 
BChE and Ro 02-0683 reaches a quasi steady-state 
phase. The initial phase of the inhibition follows the 
first order kinetics, wherefrom the rate constants 
of inhibition can be determined. Inhibition by Ro 
02-0683 has been described in several previous papers 
(9-11), but without reference to the rate constants for 
fluoride-resistant variants. Therefore, in the present 
work we studied the time course of inhibition of human 
BChE by Ro 02-0683, and determined inhibition rate 
constants which enabled differentiation between 
homozygote and heterozygote fluoride-resistant 
BChE. Moreover, in order to make the phenotyping 
procedure shorter we suggest measurement of BChE 




Propionylthiocholine iodide (PTCh), benzoylcholine 
chloride (BzCh), 5,5’-dithiobis(2-nitrobenzoic acid) 
(DTNB) and dibucaine hydrochloride were purchased 
from Sigma Chemical Co., USA. Ro 02-0683 
[dimethylcarbamate of (2-hydroxy-5-phenylbenzyl)tri-
methylammonium bromide] was supplied by Hoffman 
La Roche, USA. Sodium fluoride was purchased from 
Kemika, Croatia.
The serum specimens were collected at the 
Cholinesterase Investigation Unit at St. James’s 
University Hospital, Leeds, UK, during the 
Cholinesterase Proficiency Programme organized by 
Dr R. T. Evans between 1994 and 1998 (12). 
All spectrophotometric measurements were 
performed on a Cary 300 spectrophotometer (Varian, 
Inc., Australia).
Determination of BChE phenotypes 
Serum BChE specimens were phenotyped at 25 °C 
in 66.7 mM phosphate buffer (pH=7.4) by determining 
the activity and percentage inhibition (i.e. inhibitor 
numbers) of BzCh hydrolysis (50 µM) in the presence 
of dibucaine (50 µM), sodium fluoride (50 µM) or Ro 
02-0683 (10 nM) (3). The inhibition by dibucaine 
and sodium fluoride was measured immediately 
after the addition of inhibitor and substrate to the 
reaction mixture, whereas the procedure for Ro 
02-0683 inhibitor number determination required 
a 2 h preincubation of enzyme and inhibitor prior 
to the addition of substrate. The hydrolysis of 
benzoylcholine was determined from the decrease of 
absorbance measured at 240 nm. Phenotyping was 
complemented by measurement of activity with PTCh 
as described below.
BChE activity measurements 
Enzyme activities in sera with PTCh (4.0 mM final 
concentration) were determined at 25 °C in 0.1 M 
phosphate buffer (pH=7.4) and 0.3 mM DTNB using 
the Ellman spectrophotometric method (13). The final 
serum dilution was 150- or 300-times. The increase 
in absorbance was read at 412 nm (εM=14220 
M-1 cm-1) (14).
Determination of inhibition rate constants
Sera were incubated with 2.5, 10 and 30 nM 
Ro 02-0683 in the absence of substrate. Inhibition 
Figure 1  Structural formulae of Ro 02-0683
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the second-order rate constant (Table 2). Ro 02-0683 
strongly inhibited all BChE phenotypes studied except 
the atypical enzyme. The rate constants for usual 
and atypical homozygotes were in agreement with 
published data (9, 10). Neutralization of the charge 
obtained by the point mutation of aspartate 70 to 
glycine found in the atypical variant (15) results in a 
decreased reactivity of about 150-times towards the 
was stopped by the addition of PTCh (4.0 mM final 
concentration), and the extent of inhibition was 
determined as percentage of the control activity. 
The first-order rate constants (kobs) were calculated 
by linear regression analysis at any given inhibitor 
concentration (i):
   (Eqn. 1)
where v0 and vi stand for the enzyme activity in the 
absence and in the presence of inhibitor at time t. 
The second-order inhibition rate constant (ki) was 
calculated from:
ki = kobs / i    (Eqn. 2)
RESULTS AND DISCUSSION
Enzyme activities and dibucaine, sodium fluoride 
and Ro 02-0683 inhibitor numbers were determined 
in order to identify enzyme phenotype (Table 1). 
Phenotypes were classified according to published 
activities and inhibitor numbers for a great number of 
specimens and family studies coupled with DNA base 
sequence analysis (3, 12). The fluoride-resistant variant 
is less inhibited by sodium fluoride and dibucaine than 
usual enzyme. Consequently, fluoride and dibucaine 
numbers segregated well between homozygotes or 
heterozygotes for the fluoride-resistant and atypical 
variants and the usual variant. With the Ro 02-0682 
inhibitor number, defined as the percentage inhibition 
following two hours incubation, the fluoride-resistant 
variant can only be identified when present as the 
atypical-fluoride-resistant heterozygote, AF (Table 1, 
Figure 2).
The initial time course of inhibition by Ro 02-
0683 followed first-order kinetics for all inhibitor 
concentrations (Figure 3A). The first-order rate 
constant (kobs) was a linear function of Ro 02-0683 
concentration (Figure 3B), and the slope of the line is 
Table 1 Activities (±SD) of human BChE phenotypes with benzoylcholine (BzCh) and propionylthiocholine (PTCh), and dibucaine (DN), fluoride (FN) 
and Ro 02-0683 (RoN) inhibitor numbers (±SD). The number of BChE specimens is given in brackets; SD denotes standard deviation
BChE
Activity / µmol−1 min-1 ml−1 Inhibitor numbers
BzCh PTCh DN FN RoN
UU (6) 1.1 ± 0.3 5.3 ± 1.3 81.2 ± 1.4 60.5 ± 1.4 96.4 ± 1.1 
UF (5) 0.60 ± 0.08 2.6 ± 0.5 70.3 ± 4.0 46.3 ± 1.5 96.0 ± 1.0
FF (3) 0.47 ± 0.09 2.0 ± 0.3 69.2 ± 6.0 33.7 ± 4.6 92.7 ± 3.1
AF (4) 0.59 ± 0.11 2.8 ± 1.2 46.5 ± 1.2 31.1 ± 1.3 55.6 ± 2.5
AA (3) 0.58 ± 0.09 1.4 ± 0.3 24.3 ± 0.6 26.0 ± 4.6 10.0 ± 3.5
Figure 2  Time course of inhibition of human BChE (UF, AF and FF 
phenotypes) by 10 nM Ro 02-0683. The points denote 
the mean of activities measured with PTCh in at least 3 
experiments with at least 3 specimens
Table 2  Second-order rate constants, ki, for the inhibition of human 
BChE phenotypes by Ro 02-0683, and the residual % activity 
after 30 min of inhibition by 10 nM Ro 02-683. Eqn. 2 was 
applied to calculate ki (±SD) from kobs (8-13 values) obtained 




106 dm3 mol-1 min–1
% Activity
UU (6) 9.6 ± 1.5 11.5 ± 0.5
UF (5) 6.2 ± 0.6 23.5 ± 1.1
FF (3) 2.7 ± 0.6 47.0 ± 1.2
AF (4) 1.6 ± 0.4 58.8 ± 1.1
AA (3) 0.063 ± 0.004 ~ 100
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positively charged Ro 02-0683. The inhibition potency 
of Ro 02-0683 towards fluoride-resistant homozygous 
BChE was about 3-times lower than for the usual 
enzyme. This relatively small effect compared to the 
atypical variant is due to the mutation found in the 
fluoride-resistant variant, threonine 243 to methionine 
or glycine 390 to valine at sites distant from the active 
serine of the enzyme (7, 16, 17) and away from the 
BChE active site gorge (17). However, both mutations 
induce conformational changes either close to the 
catalytic triad and the choline binding site (mutation 
glycine 390 to valine) or close to the entrance of the 
active site gorge by a conformational change in the 
backbone (mutation threonine 243 to methionine). 
These conformational changes may weaken the 
binding of charged ligands and reduce signal 
transduction capability along the active site (18).
Rate constants for the heterozygotes UF and AF 
fell between the corresponding constants for the 
homozygotes as one could expect. From the time 
course of inhibition, it is possible to differentiate well all 
three fluoride-resistant phenotypes after only 30 min 
of inhibition by 10 nM Ro 02-0683. Moreover, when 
inhibition of AF enzyme proceeded for a longer time 
with lower concentrations of Ro 02-0683, deviation 
from the kinetics described by Eqn. 1 was observed 
(Figure 2). This is primarily due to the mixture of two 
BChE variants, which have different inhibition rates, 
thus making different contributions to total activity 
(10). It is possible to assume that this deviation is the 
result of decarbamoylation of the catalytic serine, but 
that is probably not so, because it is known that both 
usual and atypical BChE phenotypes decarbamoylate 
spontaneously at a similar and very slow rate (the 
half-life for decarbamoylation was about 3.5 hours; 
cf. ref. 9). As seen from Figure 2, after 120 min of 
inhibition the good resolution between different 
fluoride-resistant phenotypes disappears, and it is 
possible to differentiate only AF from other fluoride-
resistant phenotypes.
CONCLUSION
Ro 02-0683 is used in standard laboratory 
procedures for BChE phenotyping by measuring 
residual enzyme activity following two-hour inhibition. 
However, the time-dependent inhibition by Ro 02-
0683 is a valuable aid for distinguishing between 
these phenotypes, especially UF and FF, and more 
reliable than reversible inhibition by dibucaine and 
sodium fluoride. Therefore, we suggest reducing 
the inhibition time by Ro 02-0683 from two hours 
to 30 min, when the time course of inhibition better 
reveals the difference between fluoride-resistant 
phenotypes.
Figure 3  Progressive inhibition of human fluoride-resistant BChE phenotype (FF) by Ro 02-0683. Points denote experimental values from experiments 
with 3 specimens. The slopes of the lines on plot (A), kobs, were plotted as a function of Ro 02-0683 concentrations on plot (B). The overall 
inhibition rate constant, ki, is the slope of the line on plot (B) (cf. Eqns. 1 and 2)
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Saetak
POBOLJŠANJE RAZLUÈIVANJA FENOTIPOVA BUTIRILKOLINESTERAZE S FLUORID-
REZISTENTNOM INAÈICOM
Ispravno prepoznavanje inaèica (varijanti) butirilkolinesteraze (BChE; EC 3.1.1.8) u ljudskom serumu nuno 
je kako bi se identificirali pacijenti osjetljivi na produljeno djelovanje kratkodjelujuæih mišiænih relaksansa 
poput suksametonija (sukcinildikolina). Atipièna (A) i fluorid-rezistentna (F) inaèica normalne, obiène (U) 
BChE veoma sporo razgraðuju suksametonij, pa njegova primjena kod pacijenta moe izazvati produenu 
paralizu mišiæa. Da bi se odredile inaèice BChE, odnosno fenotip, u serumu se odreðuje inhibicija aktivnosti 
BChE sa specifiènim inhibitorima. U standardnom postupku fenotipiziranja rabi se dvosatna inhibicija 
BChE dimetilnim karbamatom Ro 02-0683. Tako duga inhibicija omoguæuje dobro razlikovanje normalne 
i atipiène inaèice BChE, ali ne i fluorid-rezistentne inaèice. U ovom radu odreðene su konstante brzine 
inhibicije iz poèetnog dijela vremenskog toka inhibicije homozigota (FF) i heterozigota (UF i AF) BChE 
s Ro 02-0683: 1.6x106, 2.7x106 i 6.2x106 dm3 mol-1min-1 za AF, FF i UF. Prema vrijednosti ovih konstanti 
fenotipovi se mogu dobro razlikovati. Nakon samo 30 minuta inhibicije razluèivanje izmeðu ovih fenotipova 
bolje je nego nakon dva sata. Stoga je preporuka da se u rutinskom postupku odreðivanja fenotipova 
BChE vrijeme inhibicije skrati s dva sata na 30 minuta. 
KLJUÈNE RIJEÈI: fenotipiziranje, fluorid-rezistentne varijante, konstante brzine inhibicije, ljudska 
butirilkolinesteraza, Ro 02-0683, suksametonij
REQUESTS FOR REPRINTS:
Zrinka Kovarik, Ph. D.
Institute for Medical Research and Occupational Health
Ksaverska c. 2, P. O. Box 291
HR-10001 Zagreb, Croatia
E-mail: zkovarik@imi.hr
